秋水仙碱对急性心肌梗死心肌损伤的影响
这项双盲多中心随机对照试验纳入192例首次ST段抬高型心肌梗死并接受直接经皮冠状动脉介入治疗的患者,比较口服秋水仙碱(2 mg负荷后0.5 mg每日两次)与安慰剂从入院至第5天对心肌损伤的作用。结果显示,第5天心脏磁共振评估的心肌梗死面积在两组间无显著差异(26 g vs 28.4 g,P=0.87),3个月左室重构和梗死面积亦无显著差异,但秋水仙碱组胃肠道不良事件发生率更高(34% vs 11%,P=0.0002)。
要点
- 秋水仙碱未显著降低第5天心脏磁共振评估的心肌梗死面积(P=0.87)。
- 3个月左室舒张末期容积变化和梗死面积两组间无显著差异。
- 秋水仙碱组胃肠道不良事件发生率显著高于安慰剂组(34% vs 11%,P=0.0002)。
核心结论
- 在再灌注时开始并持续5天口服高剂量秋水仙碱未减少心脏磁共振评估的心肌梗死面积。
研究设计与样本
- 双盲多中心随机对照试验,纳入192例首次ST段抬高型心肌梗死并接受直接经皮冠状动脉介入治疗的患者,秋水仙碱组101例,对照组91例。
- 干预为口服秋水仙碱(2 mg负荷剂量后0.5 mg每日两次)或匹配安慰剂,从入院至第5天。
- 主要疗效终点为第5天心脏磁共振成像确定的心肌梗死面积。
主要发现
- 第5天钆增强定义的心肌梗死面积在秋水仙碱组与安慰剂组间无差异,均值分别为26(IQR 16-44)g左室质量和28.4(IQR 14-40)g左室质量(P=0.87)。
- 3个月随访时,左室舒张末期容积变化在秋水仙碱组为+2.4%(IQR -8.3%至11.1%),安慰剂组为-1.1%(IQR -8.0%至9.9%),组间无显著差异(P=0.49)。
- 3个月心肌梗死面积在秋水仙碱组为17(IQR 10-28)g左室质量,安慰剂组为18(IQR 10-27)g左室质量,组间无显著差异(P=0.92)。
- 治疗期间胃肠道不良事件发生率秋水仙碱组为34%,安慰剂组为11%(P=0.0002)。
临床怎么用
- 对于首次ST段抬高型心肌梗死接受直接经皮冠状动脉介入治疗的患者,急性期使用高剂量秋水仙碱并未显示减少心肌梗死面积或改善左室重构的获益。
- 使用秋水仙碱时需注意胃肠道不良事件风险增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inflammation is a key factor of myocardial damage in reperfused ST-segment-elevation myocardial infarction. We hypothesized that colchicine, a potent anti-inflammatory agent, may reduce infarct size (IS) and left ventricular (LV) remodeling at the acute phase of ST-segment-elevation myocardial infarction. METHODS: In this double-blind multicenter trial, we randomly assigned patients admitted for a first episode of ST-segment-elevation myocardial infarction referred for primary percutaneous coronary intervention to receive oral colchicine (2-mg loading dose followed by 0.5 mg twice a day) or matching placebo from admission to day 5. The primary efficacy outcome was IS determined by cardiac magnetic resonance imaging at 5 days. The relative LV end-diastolic volume change at 3 months and IS at 3 months assessed by cardiac magnetic resonance imaging were among the secondary outcomes. RESULTS: We enrolled 192 patients, 101 in the colchicine group and 91 in the control group. At 5 days, the gadolinium enhancement-defined IS did not differ between the colchicine and placebo groups with a mean of 26 interquartile range (IQR) [16-44] versus 28.4 IQR [14-40] g of LV mass, respectively (P=0.87). At 3 months follow-up, there was no significant difference in LV remodeling between the colchicine and placebo groups with a +2.4% (IQR, -8.3% to 11.1%) versus -1.1% (IQR, -8.0% to 9.9%) change in LV end-diastolic volume (P=0.49). Infarct size at 3 months was also not significantly different between the colchicine and placebo groups (17 IQR [10-28] versus 18 IQR [10-27] g of LV mass, respectively; P=0.92). The incidence of gastrointestinal adverse events during the treatment period was greater with colchicine than with placebo (34% versus 11%, respectively; P=0.0002). CONCLUSIONS: In this randomized, placebo-controlled trial, oral administration of high-dose colchicine at the time of reperfusion and for 5 days did not reduce IS assessed by cardiac magnetic resonance imaging. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03156816.
引用
- Mewton N, Roubille F, Bresson D, et al. Effect of Colchicine on Myocardial Injury in Acute Myocardial Infarction. Circulation. 2021. PMID: 34420373. doi:10.1161/CIRCULATIONAHA.121.056177
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。